BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsCommercial

Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience CHICAGO --(BUSINESS WIRE)--Nov. 2, 2026-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company

Related news

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

TNXPTonix Pharmaceuticals2026-10-15 11:00 EST

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

TNXPTonix Pharmaceuticals2026-09-08 11:00 EST

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

ECORelectroCore2026-11-05 13:00 EST

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ECORelectroCore2026-10-21 12:00 EST

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

ALKSAlkermes plc2026-09-10 11:00 EST

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

ALKSAlkermes plc2026-09-16 11:00 EST

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

XERSXeris Pharmaceuticals2026-11-02 13:00 EST

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

XERSXeris Pharmaceuticals2026-10-02 21:00 EST

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
13.08 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States